- Reaction score
- 316
Look for trial result again, those Seti Androgenetic Alopecia trials heh, and Fevi was the same useless sh*t.
Fact is, Cots from Follica stated it some years ago now, PGD2 is a dead end, they've also use it during their trials.
You can find all patents from Follica with their various treatments mixtures (including their own PGD2 antagonists), we don't know yet the final composition of Follica's compound but you most likely won't find anything about this
Idiot
Cots did never state that. That being said not everyone responds to Crth2 therapy. There is also a study implying ptgds inhibitors might be more interesting, but thats a complete different task as there are two enzymes for it that constantly renew (h-pgds, l-pgds). H-PGDS inhibititors might actually end up on the market for duchenne.
Also ppl forget this is a regulatory issue. PGD2 is just a small part of his research. Did they simultanously apply pge2? no. did they use the new follica device on the seti trial subjects? no. Did they apply a wnt agonist? no. Did they apply fgf9 after wounding that wasnt done? no. What about shh? Nope.
In fact trials subjects could have been faulty as well (already stable using finasteride, nizoral, minoxidil, ru... - they cant really test for this in clinical trials)
I wish ppl would pay a bit more respect to ppl who keep being active and pushing hair loss research and actually getting stuff on the market.
WAY316606 was something cots was also interested in. They pussied out and look now for an analogue that they can sell after one safety trial as cosmetic. Brotzu snakeoil was best proof that this is unlikely to work.